Gefitinib is supplied in 250 mg tablets; the recommended daily dose being 250 mg once daily, with or without food. The elimination half-life is 48 hours and the mean bioavailability is 60%.

The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated with an increased risk of therapy-related ...

NICE said there is clinical trial evidence showing that Tagrisso stalls cancer growth longer than treatment with two older EGFR drugs, Roche’s Tarceva (erlotinib) and AZ’s Iressa (gefitinib).

or AZ’s Iressa (gefitinib). NICE has ruled that Tagrisso does not meet its end of life criteria, which allows for more flexibility in pricing, as existing drugs are doing enough to prolong ...

We have summarized in this article the current state of combination therapy of approved targeted drugs and irradiation. Since the introduction of the first targeted compounds almost (trastuzumab ...

Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea ...

#' @description Argyropoulos and Unruh (2015) published reconstructed IPASS clinical trial data. Despite being reconstructed, this data set retains all of the features shown in references, as well as ...

Approval based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years In the trial, Tagrisso reduced the risk of disease progression ...

Cancer chemotherapy is in evolution from non-specific cytotoxic drugs that damage both tumour and normal cells to more specific agents and immunotherapy approaches. Targeted agents are directed at ...